CRBU
4:05 PM
Caribou Biosciences to Evaluate Strategic Alternatives
-- Company to evaluate strategic alternatives to maximize stockholder value -- -- Caribou plans to discontinue vispa-cel and CB-011 allogeneic CAR-T cell therapy programs -- -- Cash, cash equivalents, and marketable securities of $113.8 million as of June 30, 2026 -- BERKELEY, Calif., Oct.
cariboubio.com